Literature DB >> 16177942

[Asymptomatic atrial fibrillation with systematic screening using tele-ECG--relevance for anticoagulation in paroxysmal atrial fibrillation].

M Patten1.   

Abstract

Event recorder monitoring plays an important role in the early detection and diagnosis of rhythm disorders such as atrial fibrillation (AF). In a recent study over 1000 patients with symptomatic paroxysmal AF were followed up by daily and symptom triggered ECG self monitoring. Independent of the presence of antiarrhythmic therapy, the incidence of AF was much higher than expected, since over 50% of AF episodes were asymptomatic. Therefore, patients symptoms are not a reliable surrogate parameter for the detection of AF. Moreover, antiarrhythmic therapy does not totally prevent atrial fibrillation, but raises the risk of silent AF episodes by reducing the mean heart rate. Based on these findings, effective anticoagulation should be taken into consideration in patients with paroxysmal AF independent of antiarrhythmic medication. The decision for anticoagulation with cumarine derivates or aspirin is dependent on the age, underlying diseases, and the individual thromboembolic risk in these patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177942     DOI: 10.1007/s00399-005-0475-8

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  18 in total

1.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

2.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

3.  Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.

Authors:  M Jones; P McEwan; C Ll Morgan; J R Peters; J Goodfellow; C J Currie
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

4.  Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation.

Authors:  Gaetano Senatore; Giuseppe Stabile; Emanuele Bertaglia; Giovanni Donnici; Antonio De Simone; Franco Zoppo; Pietro Turco; Pietro Pascotto; Massimo Fazzari
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

5.  Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin.

Authors:  C J Currie; M Jones; J Goodfellow; P McEwan; C L Morgan; C Emmas; J R Peters
Journal:  Heart       Date:  2005-05-09       Impact factor: 5.994

6.  Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.

Authors:  Gregory W Albers; Hans-Christoph Diener; Lars Frison; Margaretha Grind; Mark Nevinson; Stephen Partridge; Jonathan L Halperin; Jay Horrow; S Bertil Olsson; Palle Petersen; Alec Vahanian
Journal:  JAMA       Date:  2005-02-09       Impact factor: 56.272

7.  Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.

Authors:  David G Sherman; Soo G Kim; Bradley S Boop; Scott D Corley; John P Dimarco; Robert G Hart; L Julian Haywood; Keith Hoyte; Elizabeth S Kaufman; Michael H Kim; Elaine Nasco; Albert L Waldo
Journal:  Arch Intern Med       Date:  2005-05-23

8.  Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study.

Authors:  W J Manning; D I Silverman; C S Keighley; P Oettgen; P S Douglas
Journal:  J Am Coll Cardiol       Date:  1995-05       Impact factor: 24.094

9.  Stroke Prevention in Atrial Fibrillation Study. Final results.

Authors: 
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

10.  Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.

Authors:  Thomas Fetsch; Peter Bauer; Rolf Engberding; Hans P Koch; Jan Lukl; Thomas Meinertz; Michael Oeff; Ludger Seipel; Hans J Trappe; Norbert Treese; Günter Breithardt
Journal:  Eur Heart J       Date:  2004-08       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.